Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence

Promising oncological results have been reported for salvage lymph node dissection (SLND) with prostate-specific membrane antigen–radioguided surgery (PSMA-RGS) in patients with prostate cancer (PCa) recurrence. We performed a proof-of-principle study assessing circulating tumour cells (CTCs) as a p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sophie Knipper, Sabine Riethdorf, Stefan Werner, Derya Tilki, Markus Graefen, Klaus Pantel, Tobias Maurer
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Circulating tumour cells Salvage lymph node dissection Radioguided surgery Oncological outcomes Positron emission tomography imaging Prostate-specific membrane antigen Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fb8392c0e4e24c03a885b6f6c00a1c64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb8392c0e4e24c03a885b6f6c00a1c64
record_format	dspace
spelling	oai:doaj.org-article:fb8392c0e4e24c03a885b6f6c00a1c642021-11-04T04:40:00ZPossible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence2666-168310.1016/j.euros.2021.09.017https://doaj.org/article/fb8392c0e4e24c03a885b6f6c00a1c642021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666168321016980https://doaj.org/toc/2666-1683Promising oncological results have been reported for salvage lymph node dissection (SLND) with prostate-specific membrane antigen–radioguided surgery (PSMA-RGS) in patients with prostate cancer (PCa) recurrence. We performed a proof-of-principle study assessing circulating tumour cells (CTCs) as a prognostic marker in patients undergoing SLND. Twenty consecutive patients with recurrent PCa treated with PSMA-RGS during April–July 2019 for PSMA-positive LNs were evaluated. Preoperative CTC counts were assessed using the US Food and Drug Administration–approved CellSearch system. Biochemical recurrence (BCR)-free survival (BFS) and therapy-free survival (TFS) were evaluated using the Kaplan-Meier method. Overall, three patients (15%) were CTC-positive. Postoperatively, CTC-positive patients had more pathologically positive LNs (median 8 vs 2) without a difference in overall LN count. During median follow-up of 10.1 mo, 14 patients experienced BCR and five received further therapy. In Kaplan-Meier analyses, median BFS was 1.4 versus 4.3 mo and median TFS was 10.3 mo versus not reached for CTC-positive versus CTC-negative patients. The main limitations are the small number of patients, the retrospective design, and short follow-up. Our pilot study suggests that CTC-positive patients seem to have worse pathological and short-term oncological outcomes. Therefore, further validation of this biomarker for treatment decision-making before local salvage therapy could be of value. Patient summary: We looked at outcomes for lymph node dissection in patients with recurrence of prostate cancer. We found that outcomes appear to be worse when circulating tumour cells (CTCs) can be measured in the blood preoperatively. We conclude that detection of CTCs indicates spread of tumour cells via the blood, which may limit the benefit of lymph node dissection. Thus, CTCs should be investigated in further studies as a potential marker to help in selecting patients who could benefit from lymph node dissection if their prostate cancer recurs.Sophie KnipperSabine RiethdorfStefan WernerDerya TilkiMarkus GraefenKlaus PantelTobias MaurerElsevierarticleCirculating tumour cellsSalvage lymph node dissectionRadioguided surgeryOncological outcomesPositron emission tomography imagingProstate-specific membrane antigenDiseases of the genitourinary system. UrologyRC870-923Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENEuropean Urology Open Science, Vol 34, Iss , Pp 55-58 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Circulating tumour cells Salvage lymph node dissection Radioguided surgery Oncological outcomes Positron emission tomography imaging Prostate-specific membrane antigen Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Circulating tumour cells Salvage lymph node dissection Radioguided surgery Oncological outcomes Positron emission tomography imaging Prostate-specific membrane antigen Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sophie Knipper Sabine Riethdorf Stefan Werner Derya Tilki Markus Graefen Klaus Pantel Tobias Maurer Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
description	Promising oncological results have been reported for salvage lymph node dissection (SLND) with prostate-specific membrane antigen–radioguided surgery (PSMA-RGS) in patients with prostate cancer (PCa) recurrence. We performed a proof-of-principle study assessing circulating tumour cells (CTCs) as a prognostic marker in patients undergoing SLND. Twenty consecutive patients with recurrent PCa treated with PSMA-RGS during April–July 2019 for PSMA-positive LNs were evaluated. Preoperative CTC counts were assessed using the US Food and Drug Administration–approved CellSearch system. Biochemical recurrence (BCR)-free survival (BFS) and therapy-free survival (TFS) were evaluated using the Kaplan-Meier method. Overall, three patients (15%) were CTC-positive. Postoperatively, CTC-positive patients had more pathologically positive LNs (median 8 vs 2) without a difference in overall LN count. During median follow-up of 10.1 mo, 14 patients experienced BCR and five received further therapy. In Kaplan-Meier analyses, median BFS was 1.4 versus 4.3 mo and median TFS was 10.3 mo versus not reached for CTC-positive versus CTC-negative patients. The main limitations are the small number of patients, the retrospective design, and short follow-up. Our pilot study suggests that CTC-positive patients seem to have worse pathological and short-term oncological outcomes. Therefore, further validation of this biomarker for treatment decision-making before local salvage therapy could be of value. Patient summary: We looked at outcomes for lymph node dissection in patients with recurrence of prostate cancer. We found that outcomes appear to be worse when circulating tumour cells (CTCs) can be measured in the blood preoperatively. We conclude that detection of CTCs indicates spread of tumour cells via the blood, which may limit the benefit of lymph node dissection. Thus, CTCs should be investigated in further studies as a potential marker to help in selecting patients who could benefit from lymph node dissection if their prostate cancer recurs.
format	article
author	Sophie Knipper Sabine Riethdorf Stefan Werner Derya Tilki Markus Graefen Klaus Pantel Tobias Maurer
author_facet	Sophie Knipper Sabine Riethdorf Stefan Werner Derya Tilki Markus Graefen Klaus Pantel Tobias Maurer
author_sort	Sophie Knipper
title	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
title_short	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
title_full	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
title_fullStr	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
title_full_unstemmed	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
title_sort	possible role of circulating tumour cells for prediction of salvage lymph node dissection outcome in patients with early prostate cancer recurrence
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/fb8392c0e4e24c03a885b6f6c00a1c64
work_keys_str_mv	AT sophieknipper possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT sabineriethdorf possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT stefanwerner possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT deryatilki possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT markusgraefen possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT klauspantel possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence AT tobiasmaurer possibleroleofcirculatingtumourcellsforpredictionofsalvagelymphnodedissectionoutcomeinpatientswithearlyprostatecancerrecurrence
_version_	1718445248882933760

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence

Ejemplares similares